No Data
Ingredient stocks Scientia ADRCollecia rose 9.44% Biomea Fusion, Dyne, First Day Biopharmaceuticals, and Verve Therapeutics also rose 8.24%-6.89% Travere Therapeutics, SAGE Therapeutics, and Triharmonics rose 7.13% - 7.92% Prime MedicineEze rose 6.64% Rap
Ingredient stocks Scientia ADRCollecia rose 9.44% Biomea Fusion, Dyne, First Day Biopharmaceuticals, and Verve Therapeutics also rose 8.24%-6.89% Travere Therapeutics, SAGE Therapeutics, and Triharmonics rose 7.13% - 7.92% Prime MedicineEze rose 6.64% Rapt Therapeutics rose 11.50% RAPT T
MEME stocks are back strongly! GME surged nearly 180% in two days. Who will be next?
The agency believes that more retail traders will join this trend in the next few days, but the possibility of reaching the level of 2021 is still relatively low.
Biomea Fusion Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Biomea Fusion Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : Biomea Fusion (BMEA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $50.00.
HC Wainwright & Co. : Biomea Fusion (BMEA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $50.00.
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $50 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $50 price target.
Biomea Fusion Is Maintained at Neutral by JP Morgan
Biomea Fusion Is Maintained at Neutral by JP Morgan